Effect of Sylimarin versus placebo on the reduction of liver complication of Teriflunomide in patients with multiple sclerosis

INTERVENTION: Intervention 1: Intervention group: Triflunomide tablet 14 mg daily plus silymarin tablet 140 mg twice daily for 2 months. Intervention 2: Control group: Triflunomide tablet 14 mg daily plus placebo tablet (starch) twice a day for 2 months. CONDITION: Multiple sclerosis. ; Multiple sclerosis PRIMARY OUTCOME: Liver and biliary function tests (including AST, ALT, ALP, bilirubin and GGT). Timepoint: Before the intervention and one and two months after the intervention. Method of measurement: By laboratory test. INCLUSION CRITERIA: Age 18 to 70 years Multiple sclerosis